Proprietary biosensing meets on-device machine learning. Detecting DVT hours before conventional diagnostics can.
The Challenge
Current DVT monitoring is fundamentally episodic — ultrasound at fixed intervals, D-dimer from venous blood draws. The diagnostic window is too narrow. By the time a clot is ultrasound-visible, the coagulation cascade has been active for hours. Clinical scoring systems (Wells, YEARS) and CT scans are fraught with delayed diagnosis and radiation exposure.
"Arteria provides the first continuous molecular-level window into coagulation activation, detecting coagulation activation hours before any mechanical clot is ultrasound-visible."
Our Innovation
Three integrated innovations in one wearable patch. Molecular-level coagulation monitoring that detects DVT hours before mechanical ultrasound, targeting the primary anatomical site of DVT initiation.
A novel biosensing approach optimized for coagulation biomarker detection at diagnostically relevant concentrations — achieving sensitivity levels unreachable by conventional electrode designs.
A microneedle array penetrates only the outermost skin layer, accessing interstitial fluid without blood contact. Biomarker concentrations in ISF closely track plasma levels — enabling continuous monitoring without any needle stick.
A temporal machine learning model runs entirely on-device, learning the characteristic multi-biomarker trajectory of early coagulation cascade activation — issuing alerts hours before a clot becomes mechanically detectable.
Deep Dive
A proprietary multi-biomarker panel. On-device temporal intelligence. Real-time cascade detection — issuing alerts hours before conventional diagnostics.
Earliest Indicator
Released at the first moment of cascade activation. Most stable marker in interstitial fluid.
Secondary Confirmation
Follows primary activation. Confirms coagulation cascade progression rather than transient fluctuation.
Tertiary Signal
Elevated after clot consolidation. Provides systemic confirmation and rules out false positives.
Road Map
Building our first-generation wearable architecture. Biosensor design, device fabrication, and processing pipeline are actively advancing toward clinical validation.
In-vitro testing of biosensor performance, biomarker selectivity, and temporal ML model accuracy across synthetic plasma and ISF samples.
Partnering with leading hospitals to monitor high-risk post-operative patients, validating detection lead-time over conventional imaging under real clinical conditions.
FDA De Novo submission with supporting clinical evidence. Pursuing breakthrough device designation to accelerate review timeline and access to market.
Scaling manufacturing, establishing hospital partnerships, and launching a continuous monitoring subscription model targeting high-acuity inpatient settings.
Who We Serve
Surgical immobility is the leading trigger of DVT. Arteria provides continuous watch during the highest-risk recovery window.
Procoagulant factors in oncology dramatically elevate clot risk. Arteria enables clinicians to preempt thrombotic events before they escalate.
Long-term immobility patients in the ICU or care facilities represent a high-risk population with limited continuous monitoring options today.
Pregnancy increases DVT risk up to 5×. Arteria offers a non-invasive route to continuous surveillance without radiation or repeated blood draws.
Get In Touch
Whether you're a healthcare provider, investor, or potential partner, we'd love to hear from you. Join us in revolutionizing clot detection.